Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentuximab + paclitaxel vs placebo + paclitaxel in advanced gastric or gastroesophageal junction adenocarcinoma after first-line failure
CTR20220815Phase 3Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of gentuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Apr 2022; status: completed.
02
Drugs
gentuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20220815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220815.